CS258787A2 - Method of biologically active compounds solubilization - Google Patents

Method of biologically active compounds solubilization

Info

Publication number
CS258787A2
CS258787A2 CS872587A CS258787A CS258787A2 CS 258787 A2 CS258787 A2 CS 258787A2 CS 872587 A CS872587 A CS 872587A CS 258787 A CS258787 A CS 258787A CS 258787 A2 CS258787 A2 CS 258787A2
Authority
CS
Czechoslovakia
Prior art keywords
solubilization
biologically active
active compounds
active compound
weight
Prior art date
Application number
CS872587A
Other languages
English (en)
Other versions
CS270560B2 (en
Inventor
Karl-Erik L Falk
Sven M Hugosson
Adam Rosinski
John A Sjorgen
Original Assignee
Haessle Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20364135&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CS258787(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Haessle Ab filed Critical Haessle Ab
Publication of CS258787A2 publication Critical patent/CS258787A2/cs
Publication of CS270560B2 publication Critical patent/CS270560B2/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CS872587A 1986-04-11 1987-04-10 Method of biologically active compounds solubilization CS270560B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8601624A SE8601624D0 (sv) 1986-04-11 1986-04-11 New pharmaceutical preparations

Publications (2)

Publication Number Publication Date
CS258787A2 true CS258787A2 (en) 1989-11-14
CS270560B2 CS270560B2 (en) 1990-07-12

Family

ID=20364135

Family Applications (1)

Application Number Title Priority Date Filing Date
CS872587A CS270560B2 (en) 1986-04-11 1987-04-10 Method of biologically active compounds solubilization

Country Status (34)

Country Link
US (1) US4803081A (cs)
EP (1) EP0249587B1 (cs)
JP (1) JPH0778016B2 (cs)
KR (2) KR870009720A (cs)
CN (1) CN1025150C (cs)
AT (1) ATE76288T1 (cs)
AU (1) AU602677B2 (cs)
CA (1) CA1304294C (cs)
CS (1) CS270560B2 (cs)
CY (1) CY1826A (cs)
DD (1) DD263231A5 (cs)
DE (1) DE3779183D1 (cs)
DK (1) DK173033B1 (cs)
DZ (1) DZ1067A1 (cs)
EG (1) EG18265A (cs)
ES (1) ES2031929T3 (cs)
FI (1) FI91826C (cs)
GR (1) GR3005286T3 (cs)
HK (1) HK26795A (cs)
HU (1) HU204699B (cs)
IE (1) IE59419B1 (cs)
IS (1) IS1553B (cs)
MY (1) MY101553A (cs)
NO (1) NO174795B (cs)
NZ (1) NZ219633A (cs)
PH (1) PH22494A (cs)
PL (1) PL265078A1 (cs)
PT (1) PT84663B (cs)
SE (1) SE8601624D0 (cs)
SG (1) SG4295G (cs)
SU (1) SU1743332A3 (cs)
UA (1) UA12336A (cs)
YU (1) YU47258B (cs)
ZA (1) ZA871911B (cs)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
NO883326L (no) * 1987-08-11 1989-02-13 Bayer Ag Dhp-retard-tilberedning.
DE3738236A1 (de) * 1987-11-11 1989-05-24 Euro Celtique Sa Beisskapsel
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US4946684A (en) * 1989-06-20 1990-08-07 American Home Products Corporation Fast dissolving dosage forms
US5006344A (en) * 1989-07-10 1991-04-09 E. R. Squibb & Sons, Inc. Fosinopril tablet formulations
HU208491B (en) * 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
US5834496A (en) * 1991-12-02 1998-11-10 Sepracor, Inc. Methods for treating hypertension using optically pure S(-) felodipine
US5681812A (en) * 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
AU3243393A (en) * 1991-12-10 1993-07-19 Rush - Presbyterian - St. Luke's Medical Center Methods and compositions for reducing multi-drug resistance
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
JP3631490B2 (ja) 1992-05-13 2005-03-23 ノバルティス ファーマ株式会社 シクロスポリン含有眼科用組成物
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
DK0661045T3 (da) 1992-09-18 2002-10-28 Yamanouchi Pharma Co Ltd Hydrogelpræparat med forsinket frigivelse
JP3598049B2 (ja) * 1992-09-18 2004-12-08 山之内製薬株式会社 ハイドロゲル徐放性製剤
DK0589843T3 (da) 1992-09-25 2002-04-02 Novartis Ag Cyclosporinholdige farmaceutiske præparater
BE1006990A5 (nl) * 1993-04-22 1995-02-07 Univ Gent Werkwijze en samenstelling om een aktief bestanddeel in een vaste toedieningsvorm te brengen.
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
DE4340781C3 (de) * 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
US6093420A (en) 1996-07-08 2000-07-25 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
ES2229473T3 (es) 1997-01-30 2005-04-16 Novartis Ag Composiciones farmaceuticas sin aceite que contienen ciclosporina a.
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
AR017512A1 (es) 1997-08-22 2001-09-12 Smithkline Beecham Corp Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
SE9902742D0 (sv) * 1999-07-20 1999-07-20 Astra Ab New pharmaceutical formultion
NZ511900A (en) * 1999-09-30 2003-06-30 Penwest Pharmaceuticals Co Sustained release matrix systems for highly soluble drugs
FR2802424B1 (fr) * 1999-12-17 2002-02-15 Adir Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
CZ301790B6 (cs) 2000-04-11 2010-06-23 Sankyo Company Limited Farmaceutický prípravek obsahující blokátor vápníku
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
SE0004671D0 (sv) * 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
WO2002056883A1 (en) * 2001-01-18 2002-07-25 Wockhardt Limited Preparation of micron-size felodipine particles by microfluidization
DE60219478T2 (de) * 2001-07-06 2008-01-03 Endo Pharmaceuticals Inc. Orale gabe von 6-hydroxy-oxymorphon als analgetikum
ATE376826T1 (de) * 2001-09-28 2007-11-15 Mcneil Ppc Inc Darreichungsformen zur modifizierten freisetzung
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
TWI324074B (en) * 2001-10-09 2010-05-01 Bristol Myers Squibb Co Flashmelt oral dosage formulation
US6726931B2 (en) * 2002-04-08 2004-04-27 Standard Chem. & Pharm. Co., Ltd. Process for preparing oral sustained-release formulation of felodipine
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
ATE407674T1 (de) 2002-04-09 2008-09-15 Flamel Tech Sa Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
US20030211149A1 (en) * 2002-05-07 2003-11-13 Sherman Bernard Charles Extended release tablets comprising felodipine
JP4563642B2 (ja) * 2002-05-31 2010-10-13 ワトソン ラボラトリーズ、インコーポレイテッド 医薬製剤
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
JP2006511541A (ja) * 2002-12-17 2006-04-06 アボット ゲーエムベーハー ウント カンパニー カーゲー フェノフィブル酸、その生理学的に許容し得る塩または誘導体を含有してなる製剤
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
US20050032879A1 (en) * 2003-08-07 2005-02-10 Temple Okarter Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
EP1750717B1 (en) * 2004-02-11 2017-07-19 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
KR100598326B1 (ko) * 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
DK1915137T3 (da) * 2005-08-10 2013-11-04 Add Advanced Drug Delivery Technologies Ltd Oralt præparat med kontrolleret frisætning
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
TW200806648A (en) * 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
CN101103964B (zh) * 2006-07-14 2010-09-29 海南盛科生命科学研究院 一种含有非洛地平的缓释制剂及其制备方法
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US9419566B2 (en) 2011-04-20 2016-08-16 Freescale Semiconductor, Inc. Amplifiers and related integrated circuits
CN104997750B (zh) * 2015-07-30 2018-03-20 杭州康恩贝制药有限公司 一种非洛地平缓释片及其制备方法
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
CN109200026B (zh) * 2017-07-03 2021-01-05 北京四环科宝制药有限公司 一种非洛地平缓释片及其制备方法
AU2019285170A1 (en) 2018-06-14 2021-01-28 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714065A1 (de) * 1977-03-30 1978-10-12 Boehringer Mannheim Gmbh Instillationszubereitung
JPS5495721A (en) * 1978-01-11 1979-07-28 Nippon Kayaku Co Ltd Nifedipine preparation
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
JPS58109412A (ja) * 1981-12-23 1983-06-29 Toa Eiyou Kagaku Kogyo Kk ニフエジピン固形製剤
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung
DE3400106A1 (de) * 1984-01-04 1985-07-11 Klaus-Dieter Dr. 3550 Marburg Bremecker Pharmazeutische zubereitungen mit gesteuerter arzneistoff-freisetzung
KR850700212A (ko) * 1984-03-21 1985-12-26 죠지 드모트 서방성 약제학적 캼셀제
JPS618A (ja) * 1984-06-09 1986-01-06 Sawai Seiyaku Kk ニフエジピン含有製剤
IT1178511B (it) * 1984-09-14 1987-09-09 Pharmatec Spa Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute

Also Published As

Publication number Publication date
FI871585A0 (fi) 1987-04-10
PH22494A (en) 1988-09-12
NO174795C (cs) 1994-07-13
ATE76288T1 (de) 1992-06-15
ES2031929T3 (es) 1993-01-01
NO871199L (no) 1987-10-12
EP0249587A1 (en) 1987-12-16
DK173033B1 (da) 1999-11-29
IS3214A7 (is) 1987-10-12
HK26795A (en) 1995-03-10
FI91826B (fi) 1994-05-13
IS1553B (is) 1994-08-10
IE870925L (en) 1987-10-11
YU40787A (sh) 1992-09-07
CN87102758A (zh) 1987-10-21
PT84663B (pt) 1989-11-30
CS270560B2 (en) 1990-07-12
SE8601624D0 (sv) 1986-04-11
EG18265A (en) 1992-12-30
DK154987D0 (da) 1987-03-26
KR870009720A (ko) 1987-11-30
IE59419B1 (en) 1994-02-23
SU1743332A3 (ru) 1992-06-23
GR3005286T3 (cs) 1993-05-24
PL265078A1 (en) 1988-07-21
PT84663A (en) 1987-05-01
KR950002147B1 (ko) 1995-03-14
DK154987A (da) 1987-10-12
DD263231A5 (de) 1988-12-28
SG4295G (en) 1995-06-16
DZ1067A1 (fr) 2004-09-13
MY101553A (en) 1991-12-17
JPH0778016B2 (ja) 1995-08-23
CA1304294C (en) 1992-06-30
NO174795B (no) 1994-04-05
NZ219633A (en) 1989-11-28
CN1025150C (zh) 1994-06-29
FI91826C (fi) 1994-08-25
HUT43786A (en) 1987-12-28
KR890001521A (ko) 1989-03-27
YU47258B (sh) 1995-01-31
US4803081A (en) 1989-02-07
ZA871911B (en) 1987-12-30
HU204699B (en) 1992-02-28
EP0249587B1 (en) 1992-05-20
FI871585A (fi) 1987-10-12
AU7004387A (en) 1987-10-15
DE3779183D1 (de) 1992-06-25
UA12336A (uk) 1996-12-25
JPS62242613A (ja) 1987-10-23
NO871199D0 (no) 1987-03-23
CY1826A (en) 1995-12-01
AU602677B2 (en) 1990-10-25

Similar Documents

Publication Publication Date Title
CS258787A2 (en) Method of biologically active compounds solubilization
ES8504678A1 (es) Procedimiento para la preparacion de un derivado de insulina
KR900007837A (ko) 퀴누클리딘, 약제로서 이의 용도 및 이의 제조방법
ES2062597T3 (es) Uso de dimetilamidas de acido alquilocarboxilico como inhibidores de la cristalizacion.
PH24867A (en) A method of treating conditions associated with photodamaged skin by using pharmaceutical compositions containing p(22-(5,6,7,8 tetrahydro-5,5,8,8-tetramethyl-2-naphtyl)propenyl)phenylsulfone and derivatives thereof
DE3382637D1 (de) Eine lipidloesliche substanz enthaltende waessrige fluessigkeit.
ATE93678T1 (de) Mikrobiozide jodzusammensetzung.
ES8306321A1 (es) Un procedimiento para la produccion de un preparado en crema antiinflamatorio.
DE3665320D1 (en) Stabilization of peroxidase activity in solution
HK50094A (en) Skin detergent composition
HUT38607A (en) Process for producing phenyl-ethyl-amino-propiophenone derivatives and pharmaceutical composition containing them as active agents
JPS57149220A (en) Solution of tocopherol nicotinate for filling in soft capsule
DE3479962D1 (en) Pharmaceutical preparation containing isosorbide dinitrate
TH2909A (th) องค์ประกอบสำหรับสิ่งที่ใช้ภายในปากและวิธีทำให้สารออกฤทธิ์คงตัวอยู่ภายในองค์ประกอบสำหรับสิ่งที่ใช้ภายในปาก
TH2909EX (th) องค์ประกอบสำหรับสิ่งที่ใช้ภายในปากและวิธีทำให้สารออกฤทธิ์คงตัวอยู่ภายในองค์ประกอบสำหรับสิ่งที่ใช้ภายในปาก
RO93706B1 (ro) Procedeu de stabilizare a solutiei de helebrina

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MK4A Patent expired

Effective date: 20020410